Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Demographics and Risk Factors for Non-Accidental Orthopedic Trauma.

Sivasundaram L, Trivedi NN, Gatta J, Ning AY, Kim CY, Mistovich RJ.

Clin Pediatr (Phila). 2019 Jun;58(6):618-626. doi: 10.1177/0009922819829045. Epub 2019 Feb 16.

PMID:
30773927
2.

Top 100 Most-Cited Clinical Studies of Hip and Knee Arthroplasty: The Foundation of Practice.

Piuzzi NS, Sultan AA, Gatta J, Ng M, Cantrell WA, Khlopas A, Newman JM, Sodhi N, Harwin SF, Mont MA.

Orthopedics. 2019 Mar 1;42(2):e151-e161. doi: 10.3928/01477447-20190211-05. Epub 2019 Feb 14.

PMID:
30763450
3.

Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivorans.

Becka SA, Zeiser ET, Marshall SH, Gatta JA, Nguyen K, Singh I, Greco C, Sutton GG, Fouts DE, LiPuma JJ, Papp-Wallace KM.

Diagn Microbiol Infect Dis. 2018 Nov;92(3):253-258. doi: 10.1016/j.diagmicrobio.2018.06.005. Epub 2018 Jun 18.

4.

Associations between sedentary behaviours and dietary intakes among adolescents.

Fletcher EA, McNaughton SA, Crawford D, Cleland V, Della Gatta J, Hatt J, Dollman J, Timperio A.

Public Health Nutr. 2018 Apr;21(6):1115-1122. doi: 10.1017/S136898001700372X. Epub 2018 Jan 10.

5.

Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.

Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, Falleni M, Tosi D, Borghi E, Winkler ML, Wilson BM, LiPuma JJ, Nukaga M, Bonomo RA.

ACS Infect Dis. 2017 Jul 14;3(7):502-511. doi: 10.1021/acsinfecdis.7b00020. Epub 2017 Mar 30.

6.

Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen.

Papp-Wallace KM, Becka SA, Taracila MA, Zeiser ET, Gatta JA, LiPuma JJ, Bonomo RA.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01941-16. doi: 10.1128/AAC.01941-16. Print 2017 Feb.

7.

Finding the Perfect Match: Factors That Influence Family Medicine Residency Selection.

Wright KM, Ryan ER, Gatta JL, Anderson L, Clements DS.

Fam Med. 2016 Apr;48(4):279-85.

8.

Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase.

Papp-Wallace KM, Becka SA, Taracila MA, Winkler ML, Gatta JA, Rholl DA, Schweizer HP, Bonomo RA.

Antimicrob Agents Chemother. 2015 Nov 23;60(2):777-88. doi: 10.1128/AAC.02073-15. Print 2016 Feb.

9.

Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.

Papp-Wallace KM, Bajaksouzian S, Abdelhamed AM, Foster AN, Winkler ML, Gatta JA, Nichols WW, Testa R, Bonomo RA, Jacobs MR.

Diagn Microbiol Infect Dis. 2015 May;82(1):65-9. doi: 10.1016/j.diagmicrobio.2015.02.003. Epub 2015 Feb 14.

10.

Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.

Papp-Wallace KM, Winkler ML, Gatta JA, Taracila MA, Chilakala S, Xu Y, Johnson JK, Bonomo RA.

Antimicrob Agents Chemother. 2014 Aug;58(8):4290-7. doi: 10.1128/AAC.02625-14. Epub 2014 May 12.

11.

A kinetic analysis of the inhibition of FOX-4 β-lactamase, a plasmid-mediated AmpC cephalosporinase, by monocyclic β-lactams and carbapenems.

Papp-Wallace KM, Mallo S, Bethel CR, Taracila MA, Hujer AM, Fernández A, Gatta JA, Smith KM, Xu Y, Page MG, Desarbre E, Bou G, Bonomo RA.

J Antimicrob Chemother. 2014 Mar;69(3):682-90. doi: 10.1093/jac/dkt434. Epub 2013 Nov 13.

12.

Insights into β-lactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants.

Papp-Wallace KM, Taracila MA, Gatta JA, Ohuchi N, Bonomo RA, Nukaga M.

J Biol Chem. 2013 Jun 28;288(26):19090-102. doi: 10.1074/jbc.M113.458315. Epub 2013 May 8.

13.

Program to improve colorectal cancer screening in a low-income, racially diverse population: a randomized controlled trial.

Jean-Jacques M, Kaleba EO, Gatta JL, Gracia G, Ryan ER, Choucair BN.

Ann Fam Med. 2012 Sep-Oct;10(5):412-7. doi: 10.1370/afm.1381.

14.

Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3.

Papp-Wallace KM, Senkfor B, Gatta J, Chai W, Taracila MA, Shanmugasundaram V, Han S, Zaniewski RP, Lacey BM, Tomaras AP, Skalweit MJ, Harris ME, Rice LB, Buynak JD, Bonomo RA.

Antimicrob Agents Chemother. 2012 Nov;56(11):5687-92. doi: 10.1128/AAC.01027-12. Epub 2012 Aug 20.

15.

Evaluation of a commercial microarray system for detection of SHV-, TEM-, CTX-M-, and KPC-type beta-lactamase genes in Gram-negative isolates.

Endimiani A, Hujer AM, Hujer KM, Gatta JA, Schriver AC, Jacobs MR, Rice LB, Bonomo RA.

J Clin Microbiol. 2010 Jul;48(7):2618-22. doi: 10.1128/JCM.00568-10. Epub 2010 May 26.

16.

Thermal ablation of the goat mammary gland as a model for post-lumpectomy treatment of breast cancer: preliminary observations.

Alvarado R, Mahon B, Valadez C, Caufield M, Wadhwani S, Hambleton C, Siziopikou KP, Dickler AT, Gatta J, Dowlatshahi K.

Int J Hyperthermia. 2009 Feb;25(1):47-55. doi: 10.1080/02656730802322946.

PMID:
19219700

Supplemental Content

Support Center